Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Multiple sclerosis affects a significant portion of the world's adult population and is the most common nontraumatic neuroimmunology disorder. Although the specific etiology of multiple sclerosis remains unknown, it has been associated with autoimmune components. While current treatment options relieve some symptoms in MS patients, most are immunosuppressive and only delay the progression of the disease without conferring definitive curative measures. Hence, a thorough understanding of disease pathobiology, the contribution of the neurovascular unit (NVU), and biological body-on-a-chip systems that replicate the blood-brain barrier may open new horizons for the discovery of potential therapeutics for MS.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185290PMC
http://dx.doi.org/10.3389/fimmu.2025.1595276DOI Listing

Publication Analysis

Top Keywords

multiple sclerosis
12
neurovascular unit
8
blood-brain barrier
8
sclerosis etiology
4
etiology context
4
context neurovascular
4
unit immune
4
immune system
4
system involvement
4
involvement advancements
4

Similar Publications

Natural Products for Regulation of Autoimmune Diseases: Chemical Diversity, Pharmacology, and Therapeutic Applications.

Chem Biodivers

September 2025

Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, Laboratory of Anti-Allergy Functional Compounds, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.

Autoimmune diseases (AIDs), defined by irregularities in immune system function, pose a substantial health challenge worldwide, impacting millions with persistent and frequently debilitating conditions. Conventional treatments, such as glucocorticoid-based immunosuppressive therapies, are associated with notable drawbacks and limitations. In response to these difficulties, recent scientific efforts have increasingly focused on natural compounds as potential therapeutic agents.

View Article and Find Full Text PDF

Background And Objectives: Myelitis is a relatively common clinical entity for neurologists, with diverse underlying causes. The aim of this study was to describe the incidence of myelitis, its causes, clinical presentation, and factors predicting functional outcomes and relapses.

Methods: Using the Swedish National Patient Registry, we identified all adult patients in Stockholm County between 2008 and 2018 using International Classification of Diseases, 10th Edition (ICD-10) codes likely to include myelitis.

View Article and Find Full Text PDF

Background And Objectives: While reductions in optical coherence tomography (OCT) pRNFL and ganglion cell-inner plexiform layer thicknesses have been shown to be associated with brain atrophy in adult-onset MS (AOMS) cohorts, the relationship between OCT and brain MRI measures is less established in pediatric-onset MS (POMS). Our aim was to examine the associations of OCT measures with volumetric MRI in a cohort of patients with POMS to determine whether OCT measures reflect CNS neurodegeneration in this patient population, as is seen in AOMS cohorts.

Methods: This was a cross-sectional study with retrospective ascertainment of patients with POMS evaluated at a single center with expertise in POMS and neuro-ophthalmology.

View Article and Find Full Text PDF

IL-17A is a pro-inflammatory cytokine that significantly contributes to the pathogenesis of autoimmune diseases, including multiple sclerosis (MS). Previous studies have suggested that PARP-1 inhibitors can modulate IL-17A-mediated inflammation, prompting the investigation of Niraparib, an FDA-approved PARP-1 inhibitor, as a potential therapeutic agent for MS. In this study, we hypothesized that Niraparib could disrupt the interaction between IL-17A and its receptor, IL-17RA.

View Article and Find Full Text PDF